Skip to main content
. 2018 Jul 17;6(2):124–133. doi: 10.1093/nop/npy023

Table 3.

Differences Between Patients Undergoing Initial Biopsy or Resection (n = 542, 6 Cases Missing)

Biopsy (N = 154) Resection (N = 388) P-Value
Age, Mean (SD) 53.0 (14.9) 44.0 (14.2) <.001
Female, n (%) 76 (49.4) 168 (43.3) .20
Year of Treatment, Median (IQR) 2010 (2008-2013) 2011 (2009-2013) .09
Tumor Size, n (%) N = 130 N = 349 .10
 < 4 cm 59 (45.4) 134 (38.4)
 4-6 cm 41 (31.5) 148 (42.4)
 > 6 cm 30 (23.1) 67 (19.2)
Main Lobe Involved, n (%) <.001
 Frontal 63 (40.9) 219 (56.4)
 Temporal 29 (18.8) 94 (24.2)
 Parietal 24 (15.6) 47 (12.1)
 Occipital 8 (5.2) 12 (3.1)
 Overlapping Sites 8 (5.2) 6 (1.6)
 Not Specified 22 (14.3) 10 (2.6)
Laterality, n (%) N = 149 N = 385 <.001
 Left 77 (51.7) 195 (50.6)
 Right 58 (38.9) 182 (47.3)
 Bilateral 14 (9.4) 8 (2.1)
Multifocal, n (%) 34 (22.1) 23 (5.9)
N = 387
<.001
Bilateral OR Multifocal, n (%) 38 (24.7) 25 (6.5)
N = 387
<.001
Asymptomatic, n (%) 7 (5.0)
N = 141
29 (7.8)
N = 374
.27
Focal Deficit, n (%) 76 (50.0)
N = 152
123 (32.7)
N = 376
<.001
Seizures, n (%) 86 (61.0)
N = 141
246 (67.6)
N = 364
.16
ICP-Related Symptoms, n (%) 34 (24.3)
N = 140
90 (24.8)
N = 363
.91
Performance Status, n (%) N = 149 N = 380 .001
 0 67 (45.0) 229 (60.3)
 1 44 (29.5) 93 (24.5)
 2 24 (16.1) 48 (12.6)
 3 11 (7.4) 6 (1.6)
 4 3 (2.0) 4 (1.1)
Weeks from Imaging to Surgery, Median (IQR) 4 (2-8.75)
N = 152
5 (3-12)
N = 384
.10
Histopathology, n (%) <.001
Astrocytoma 120 (77.9) 152 (39.2)
Oligoastrocytoma 11 (7.1) 171 (44.1)
Oligodendroglioma 23 (14.9) 65 (16.8)
Postop Complication, n (%) 14 (9.1) 117 (30.2) <.001
Postop New Neurological Deficit, n (%) 8 (6.2)
N = 130
78 (22.5)
N = 347
<.001
Postop New Seizure, n (%) 1 (0.8)
N = 130
10 (2.9)
N = 346
.17
Postop Infection, n (%) 3 (2.1)
N = 141
11 (3.0)
N = 361
.57
Postop VTE, n (%) 3 (2.1)
N = 141
7 (1.9)
N = 361
.89
Postop Hematoma, n (%) 3 (2.1)
N = 141
23 (6.4)
N = 361
.05
Reoperation due to Complication, n (%) 5 (3.8)
N = 130
23 (6.6)
N = 346
.25
Neurosurgical Ward, Days (IQR) 3 (2-5) 5 (3-6) <.001
Planned Adjuvant Oncological Treatment, n (%) 100 (87.0) 231 (67.2) <.001
30-day Mortality, n (%) 2 (1.3)
N = 153
5 (1.3) .99
1-Year Mortality, n (%) 41 (26.8)
N = 153
21 (5.4) <.001

Abbreviations: ICP, intracranial pressure; IQR, interquartile range; Postop, postoperative; VTE, venous thromboembolism.

When data are missing, the actual N is provided in individual cells.